Your AI-Trained Oncology Knowledge Connection!

Evan Lipson, MD

home / authors / evan-lipson-md

Articles

Closing Remarks on the Treatment of Patients With Metastatic Melanoma

Michael Atkins, MD;Evan Lipson, MD

May 17th 2022

Experts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios

Michael Atkins, MD;Evan Lipson, MD

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson discuss additional second- and third-line treatment options.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

Michael Atkins, MD;Evan Lipson, MD

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.

Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab

Michael Atkins, MD;Evan Lipson, MD

May 11th 2022

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Unmet Needs

Michael Atkins, MD;Evan Lipson, MD

May 11th 2022

Dr Michael Atkins and Dr Evan Lipson highlight some of the current unmet needs in the treatment of patients with metastatic melanoma.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: BRAF/MEK Inhibitors

Michael Atkins, MD;Evan Lipson, MD

May 5th 2022

Experts discuss the use of BRAF and MEK inhibitors as first-line treatments for patients with metastatic melanoma.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab

Michael Atkins, MD;Evan Lipson, MD

May 5th 2022

Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.

First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile

Michael Atkins, MD;Evan Lipson, MD

April 26th 2022

Dr Michael Atkins and Dr Evan Lipson introduce and discuss a patient with unresectable stage IV metastatic melanoma.

The Current State of Metastatic Melanoma

Michael Atkins, MD;Evan Lipson, MD

April 26th 2022

Dr Evan Lipson provides a brief overview of metastatic melanoma including information on incidence and prognosis. He also covers the current state of biomarker testing for patients recently diagnosed with metastatic melanoma.